A role for the Fas/FasL system in modulating genetic susceptibility to T-cell lymphoblastic lymphomas

被引:13
作者
Villa-Morales, Maria
Santos, Javier
Perez-Gomez, Eduardo
Quintanilla, Miguel
Fernandez-Piqueras, Jose [1 ]
机构
[1] Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain
[2] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28049 Madrid, Spain
关键词
D O I
10.1158/0008-5472.CAN-06-4006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Fas/FasL system mediates induced apoptosis of immature thymocytes and peripheral T lymphocytes, but little is known about its implication in genetic susceptibility to T-cell malignancies. In this article, we report that the expression of FasL increases early in all mice after gamma-radiation treatments, maintaining such high levels for a long time in mice that resisted tumor induction. However, its expression is practically absent in T-cell lymphoblastic lymphomas. Interestingly, there exist significant differences in the level of expression between two mice strains exhibiting extremely distinct susceptibilities that can be attributed to promoter functional polymorphisms. In addition, several functional nucleotide changes in the coding sequences of both Fas and FasL genes significantly affect their biological activity. These results lead us to propose that germ-line functional polymorphisms affecting either the levels of expression or the biological activity of both Fas and FasL genes could be contributing to the genetic risk to develop T-cell lymphoblastic lymphomas and support the use of radiotherapy as an adequate procedure to choose in the treatment of T-cell malignancies.
引用
收藏
页码:5107 / 5116
页数:10
相关论文
共 50 条
[1]   CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells [J].
Barnhart, BC ;
Legembre, P ;
Pietras, E ;
Bubici, C ;
Franzoso, G ;
Peter, ME .
EMBO JOURNAL, 2004, 23 (15) :3175-3185
[2]   The CD95 type I/type II model [J].
Barnhart, BC ;
Alappat, EC ;
Peter, ME .
SEMINARS IN IMMUNOLOGY, 2003, 15 (03) :185-193
[3]  
Baumann Sven, 2002, Current Molecular Medicine (Hilversum), V2, P257, DOI 10.2174/1566524024605671
[4]  
Booker JK, 1998, J IMMUNOL, V161, P4536
[5]   Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy [J].
Botti, C ;
Buglioni, S ;
Benevolo, M ;
Giannarelli, D ;
Papaldo, P ;
Cognetti, F ;
Vici, P ;
Di Filippo, F ;
Del Nonno, F ;
Venanzi, FM ;
Natali, PG ;
Mottolese, M .
CLINICAL CANCER RESEARCH, 2004, 10 (04) :1360-1365
[6]   Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response element [J].
Crist, SA ;
Griffith, TS ;
Ratliff, TL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (38) :35950-35958
[7]  
Fleck M, 1998, J IMMUNOL, V160, P3766
[8]   Signal transduction - FasL binds preassembled Fas [J].
Golstein, P .
SCIENCE, 2000, 288 (5475) :2328-2329
[9]   ACTIVATION OF A C-K-RAS ONCOGENE BY SOMATIC MUTATION IN MOUSE LYMPHOMAS INDUCED BY GAMMA-RADIATION [J].
GUERRERO, I ;
VILLASANTE, A ;
CORCES, V ;
PELLICER, A .
SCIENCE, 1984, 225 (4667) :1159-1162
[10]   Functional analysis of human promoter polymorphisms [J].
Hoogendoorn, B ;
Coleman, SL ;
Guy, CA ;
Smith, K ;
Bowen, T ;
Buckland, PR ;
O'Donovan, MC .
HUMAN MOLECULAR GENETICS, 2003, 12 (18) :2249-2254